Experienced in Hereditary Retinoblastoma

Dr. Bryan A. Faller

Hematology Oncology | Hematology | Oncology

Missouri Baptist Physician Services LLC

3015 N Ballas Rd,

Saint Louis, MO

Clinical Trials:Currently Recruiting for 2 Trials

Accepting New Patients

Offers Telehealth

Experienced in Hereditary Retinoblastoma

Missouri Baptist Physician Services LLC

3015 N Ballas Rd,

Saint Louis, MO

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bryan Faller is a Hematologist Oncology specialist and a Hematologist in Saint Louis, Missouri. Dr. Faller and is rated as an Experienced provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Lung Cancer, Colorectal Cancer, Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Bone Marrow Aspiration. Dr. Faller is currently accepting new patients.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 185 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Parkland Health Center

Barnes-Jewish St Peters Hospital

Missouri Baptist Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Humana

HMO
INDEMNITY
POS
PPO

Locations

Missouri Baptist Physician Services LLC
3015 N Ballas Rd, Saint Louis, MO 63131

Call: 314-996-5151

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

182 Clinical Trials

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study

Enrollment Status: Recruiting

Publish Date: June 04, 2025

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Enrollment Status: Recruiting

Publish Date: May 09, 2025

Intervention Type: Drug, Radiation

Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin

Study Phase: Phase 3

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Enrollment Status: Active_not_recruiting

Publish Date: June 15, 2025

Intervention Type: Drug, Biological, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Enrollment Status: Suspended

Publish Date: June 15, 2025

Intervention Type: Biological

Study Drugs: Blinatumomab, Inotuzumab

Study Phase: Phase 2

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Suspended

Publish Date: June 13, 2025

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Suspended

Publish Date: June 13, 2025

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel

Study Phase: Phase 2/Phase 3

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Other, Procedure, Drug, Biological, Radiation

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 2/Phase 3

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Other, Drug, Radiation, Procedure

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 3

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Other, Drug

Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin

Study Phase: Phase 2

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Suspended

Publish Date: June 13, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: June 12, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Enrollment Status: Active_not_recruiting

Publish Date: June 12, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: June 12, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: June 12, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: June 12, 2025

Intervention Type: Procedure, Other, Radiation, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: June 11, 2025

Intervention Type: Biological, Drug

Study Drugs: Carboplatin, Nivolumab, Paclitaxel

Study Phase: Phase 3

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Enrollment Status: Completed

Publish Date: June 11, 2025

Intervention Type: Drug

Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel

Study Phase: Phase 3

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Enrollment Status: Completed

Publish Date: June 11, 2025

Intervention Type: Drug

Study Drug: Ramipril

Study Phase: Phase 2

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Enrollment Status: Active_not_recruiting

Publish Date: June 08, 2025

Intervention Type: Other, Procedure

Study Phase: Not Applicable

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: June 06, 2025

Intervention Type: Other, Drug, Procedure, Biological

Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab

Study Phase: Phase 3

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma

Enrollment Status: Suspended

Publish Date: June 05, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Enrollment Status: Active_not_recruiting

Publish Date: June 05, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Olaparib, Temozolomide

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: June 03, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: May 30, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study

Enrollment Status: Active_not_recruiting

Publish Date: May 25, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Pembrolizumab, VLP-Encapsulated TLR9 Agonist CMP-001

Study Phase: Phase 2

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE

Enrollment Status: Active_not_recruiting

Publish Date: May 25, 2025

Intervention Type: Other, Procedure

Study Phase: Phase 2

Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

Enrollment Status: Completed

Publish Date: May 23, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Ixazomib Citrate, Lenalidomide

Study Phase: Phase 3

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: May 23, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Enrollment Status: Completed

Publish Date: May 22, 2025

Intervention Type: Drug

Study Drug: Atezolizumab

Study Phase: Phase 2

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: May 22, 2025

Intervention Type: Procedure, Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Enrollment Status: Active_not_recruiting

Publish Date: May 22, 2025

Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device

Study Drugs: Ipilimumab, Nivolumab, Temozolomide

Study Phase: Phase 2/Phase 3

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Enrollment Status: Active_not_recruiting

Publish Date: May 20, 2025

Intervention Type: Drug, Procedure

Study Drugs: Carboplatin, Letrozole, Paclitaxel

Study Phase: Phase 3

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: May 18, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 3

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: May 18, 2025

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Enrollment Status: Completed

Publish Date: May 16, 2025

Intervention Type: Other, Drug

Study Drugs: Cisplatin, Veliparib

Study Phase: Phase 2

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: May 16, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Enrollment Status: Active_not_recruiting

Publish Date: May 15, 2025

Intervention Type: Other, Dietary supplement

Study Phase: Phase 3

A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

Enrollment Status: Active_not_recruiting

Publish Date: May 14, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: May 14, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

Enrollment Status: Active_not_recruiting

Publish Date: May 13, 2025

Intervention Type: Other, Radiation

Study Phase: Phase 3

Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Enrollment Status: Active_not_recruiting

Publish Date: May 13, 2025

Intervention Type: Procedure, Biological, Drug, Other, Radiation

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C

Study Phase: Phase 2

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: May 11, 2025

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride

Study Phase: Phase 3

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: May 11, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab

Study Phase: Phase 2

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Enrollment Status: Active_not_recruiting

Publish Date: May 11, 2025

Intervention Type: Drug, Procedure, Biological

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: May 11, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma

Enrollment Status: Active_not_recruiting

Publish Date: May 09, 2025

Intervention Type: Radiation, Procedure, Drug

Study Drugs: Atezolizumab, Cisplatin, Pemetrexed Disodium

Study Phase: Phase 1

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: May 09, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 2

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Enrollment Status: Active_not_recruiting

Publish Date: May 09, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide

Study Phase: Phase 2/Phase 3

View 48 Less Clinical Trials

19 Total Publications

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2024

View All 19 Publications

Similar Doctors

Advanced in Hereditary Retinoblastoma

Dr. George Ansstas

Oncology

Advanced in Hereditary Retinoblastoma

Dr. George Ansstas

Oncology

Washington University

10 Barnes W Dr,

Saint Louis, MO

(2.8 mi)

Languages Spoken:

English, Arabic

See accepted insurances

Accepting New Patients

George Ansstas is an Oncologist in Saint Louis, Missouri. Dr. Ansstas and is rated as an Elite provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Astrocytoma, Glioblastoma, Melanoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Ansstas is currently accepting new patients.

Experienced in Hereditary Retinoblastoma

Dr. Elliot E. Abbey

Oncology | Hematology

Experienced in Hereditary Retinoblastoma

Dr. Elliot E. Abbey

Oncology | Hematology

Van Amburg And Busiek Mds LLC

232 S Woods Mill Rd, Suite 330e,

Chesterfield, MO

(3.2 mi)

314-205-6737

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Elliot Abbey is an Oncologist and a Hematologist in Chesterfield, Missouri. Dr. Abbey and is rated as a Distinguished provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Abbey is currently accepting new patients.

Experienced in Hereditary Retinoblastoma

Dr. Donald F. Busiek

Hematology Oncology | Hematology | Oncology

Experienced in Hereditary Retinoblastoma

Dr. Donald F. Busiek

Hematology Oncology | Hematology | Oncology

Van Amburg And Busiek Mds LLC

232 S Woods Mill Rd, Suite 330e,

Chesterfield, MO

(3.2 mi)

314-205-6737

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Donald Busiek is a Hematologist Oncology specialist and a Hematologist in Chesterfield, Missouri. Dr. Busiek and is rated as a Distinguished provider by MediFind in the treatment of Hereditary Retinoblastoma. His top areas of expertise are Anaplastic Large Cell Lymphoma, Lung Cancer, Thrombocytopenia, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Busiek is currently accepting new patients.

VIEW MORE HEREDITARY RETINOBLASTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Faller's expertise for a condition

ConditionClose